Dicloxacillin

Total Page：16

File Type：pdf, Size：1020Kb

Dicloxacillin Antibiotic Class: Penicillin (penicillinase-resistant penicillin) Antimicrobial Spectrum: Staphylococcus spp., Streptococcal spp. Mechanism of Action: Exerts bactericidal activity via inhibition of bacterial cell wall synthesis by binding one or more of the penicillin binding proteins (PBPs). Exerts bacterial autolytic effect by inhibition of certain PBPs related to the activation of a bacterial autolytic process. Pharmacodynamics: Penicillins produce time-dependent killing Pharmacokinetics: Cmax: 10-17mcg/ml; Oral bioavailability: 37%; Half-life: 0.8 hours; Table 6 Adverse Effects: Hematologic: agranulocytosis, eosinophilia, hemolytic anemia, neutropenia, inhibition of platelet aggregation Renal: interstitial nephritis CNS: seizures Other: Jarisch-Herxheimer Reaction (fever, chills, sweating, tachycardia, hyperventilation, flushing, and myalgia) Dosage: Adults: 125-250 mg po q6h Pediatric: > 1 month and < 40 kg: 12.5 - 25 mg/kg/day po in 4 divided doses ³ 40 kg: usual adult dose Staphylococcal osteomyelitis: 50-100 mg/kg/day in 4 divided doses Disease state based dosing: Renal failure: not necessary Contraindications/Warnings/Precautions: Contraindications: Anaphylaxis to dicloxacillin or other penicillins Precautions: Cephalosporin hypersensitivity Drug Interactions: Dicloxacillin is an inducer of the cytochrome P450 3A4 isoenzyme. Caution should be exercised and monitoring is suggested when concomitantly administering dicloxacillin with drugs that have narrow therapeutic windows and are substrates of the CYP3A4 enzyme. Contraceptives - decreased contraceptive effectiveness Live Typhoid Vaccine - decreased immunological response to the typhoid vaccine Probenecid - increased dicloxacillin levels Warfarin - decreased anticoagulant effectiveness Pregnancy: Category B: No evidence of risk in humans but studies inadequate. Monitoring Requirements: Therapeutic: Culture and sensitivities, signs and symptoms of infection Toxic: Periodic CBC, urinalysis, BUN, Creatinine, AST and ALT Brand names/Manufacturer: .

Copy Link

Recommended publications

Topical Antibiotics for Impetigo: a Review of the Clinical Effectiveness and Guidelines
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 21, 2017 Report Length: 23 Pages Authors: Rob Edge, Charlene Argáez Cite As: Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
[Show full text]
Consideration of Antibacterial Medicines As Part Of
Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
[Show full text]
Interest in the Physical, Chemical and Spectroscopic Properties of the P
VOL. XXVII NO. 3 THE JOURNAL OF ANTIBIOTICS 215 A CHIROPTICAL STUDY OF PENICILLINS L. A MITSCHER, PETER W. HOWISON* and THEODORE D. SOKOLOSKI Division of Natural Products Chemistry The Ohio State University, Columbus, Ohio 43210. U.S. A. (Received for publication November 9, 1973) ORD and CD spectra are reported for a series of penicillin antibiotics and related degradation products. The results, when compared with published X-ray data, suggest that some conformational changes can apparently go undetected by chiroptical techniques in this series and that the side chain substituent at C6 plays a relatively minor role in determining the sign and intensity of the COTTON effect unless its stereochemistry is inverted. The rather large spectroscopic effect following Ca epimerization has potential for development as an assay for the percentage of 6-epihetacillin in a given mixture. Some preliminary data are presented showing the utility of this method for investigating the kinetics of CB epimerization. Semiempirical predictive rules developed for simple amides are inadequate for rationalizing the penicillin spectra. The origin of the COTTON effects is briefly discussed and contrasted with the cephalosporin antibiotics. Interest in the physical, chemical and spectroscopic properties of the p-lactam antibiotics remains high because of their outstanding clinical utility and a desire to rationalize their mode of action on a molecular level. A recent review volume has collected much of this scattered information1). One of the techniques which has found wide application for the study of the stereo-chemistry and solution conformation of antibiotics is optical rotatory dispersion and circular dichroism spectroscopy2). Although CD measurements of the cephalosporins have been discussed 3,4) no corresponding study of the chiroptical properties of the penicillins has yet appeared except in brief extracts'.
[Show full text]
DICLOXACILLIN SODIUM- Dicloxacillin Sodium Capsule Teva Pharmaceuticals USA, Inc
DICLOXACILLIN SODIUM- dicloxacillin sodium capsule Teva Pharmaceuticals USA, Inc. ---------- Dicloxacillin Sodium Capsules USP Rx only To reduce the development of drug resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Dicloxacillin sodium, USP is a semisynthetic antibiotic substance which resists destruction by the enzyme penicillinase (beta - lactamase). It is monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5- methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylate monohydrate. Dicloxacillin is administered orally via capsule form or powder for reconstitution. Structurally, dicloxacillin sodium, USP may be represented as follows: C19H16Cl2N3NaO5 S·H2O MW 510.32 Inactive Ingredients Capsules Magnesium Stearate. Capsule Shell and Print Constituents D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #1, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake, D&C Yellow #10, Gelatin, Shellac, Sodium Lauryl Sulfate, Sorbitan Monolaurate, Black Iron Oxide, Titanium Dioxide, Propylene Glycol. CLINICAL PHARMACOLOGY Microbiology Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. bacterial cell wall. Antibacterial Activity Dicloxacillin sodium has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Gram-positive Bacteria Staphylococcus spp.
[Show full text]
Concept Paper
Concept Paper: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs Introduction This concept paper discusses a potential approach to considering the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. In 2003, FDA established a list ranking antimicrobial drugs according to their relative importance in human medicine primarily for the purpose of supporting a qualitative risk assessment process outlined in agency guidance. It was envisioned by the Agency at the time the current medical importance rankings list was published that it would periodically reassess the rankings to align with contemporary science and current human clinical practices. To that end, this paper describes a potential revised process for ranking antimicrobial drugs according to their relative importance in human medicine, potential revised criteria to determine the medical importance rankings, and the list of antimicrobial drug medical importance rankings that would result if those criteria were to be used. Disclaimer: This concept paper is for discussion purposes only. The intent of this concept paper is to obtain public comment and early input on a potential approach to consider the human medical importance of antimicrobial drugs when assessing and managing antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. This concept paper does not contain recommendations and does not constitute draft or final guidance by the Food and Drug Administration. It should not be used for any purpose other than to facilitate public comment.
[Show full text]
NDA Multidisciplinary Review and Evaluation
Multidisciplinary Review and Evaluation of Efficacy Supplemental NDA 200327 S-22 Teflaro – ceftaroline fosamil NDA Multidisciplinary Review and Evaluation Application Type sNDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) November 13, 2018 Received Date(s) November 13, 2018 PDUFA Goal Date September 13, 2019 Division/Office Division of Anti-Infective Products Office of Antimicrobial Products Review Completion Date September 4, 2019 Established/Proper Name Ceftaroline fosamil Trade Name Teflaro Pharmacologic Class Cephalosporin class of beta-lactams Code name PPI-0903 (also known as TAK-599) Applicant Allergan Sales, LLC Dosage form Injection Applicant proposed Dosing 6 mg/kg every 8 hours as a (b) (4)-minute infusion in patients Regimen <2 months of age (b) (4) Applicant Proposed No new proposed indication. Updated labeling in Section 8.4 Indication(s)/Population(s) for patients less than 2 months of age. Regulatory Action Approval Indication(s)/Population(s) Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in (if applicable) pediatric patients 0* to less than 2 months old (*Gestational age 34 weeks and older and postnatal age 12 days and older) Dosing Regimen 6 mg/kg every 8 hours by IV infusion administered over 30 to 60 min Version date: October 12, 2018 1 Reference ID: 4490056 Multidisciplinary Review and Evaluation of Efficacy Supplemental NDA 200327 S-22 Teflaro – ceftaroline fosamil Table of Contents Table of Contents ........................................................................................................
[Show full text]
Gram Positive Cocci (GPC) Gram Neg (Rods = GNR) Anaerobes
Gram Positive Cocci (GPC) Gram Neg (rods = GNR) Anaerobes Atypicals Classification Antibiotic Cluster Streptococcus Entero- Resp Enteric Non- Bacteroides, Mycoplasma = Staph β↓ & α-hemolytic↓ coccus (cocci) GI flora enteric Clostridium Legionella Beta-Lactams General Spectrum MSSA Group pneumo, faecalis H. flu, E. coli, Pseud- (non-dfficile) Chlamydia Penicillins of Activity → only A / B Viridans only M. cat Klebsiella omonas Peptostrep. (pneumonia) Natural Penicillin G IV/ PenVK PO +/- ++ + + 0 0 0 + 0 Anti- Oxacillin/Nafcillin IV, ++ ++ + 0 0 0 0 0 0 Staphylococcal Dicloxacillin PO Aminopenicillins Amp/Amoxicillin IV/PO 0 ++ + ++ +R +/- 0 + 0 Anti-Pseudomonal Piperacillin/Ticarcillin IV 0 + + + + + ++R + 0 Beta-Lactamase Clavulanate IV/PO, sulbactam Increase Inc by Increase Increase Inhibitor added tazobactam, vaborbactam IV by + + by + by + Cephalosporins Cefazolin IV/ ++ ++ +/- 0 +/- + 0 0 0 1st Generation Cephalexin PO 2nd Generation Cefuroxime IV/PO + ++ + 0 + + 0 +/- 0 Cephamycins Cefoxitin/Cefotetan IV 0 + 0 0 + + 0 + 0 3rd Generation Ceftriaxone/Cefotaxime IV + ++ ++ 0 ++ ++R 0 +/- 0 (PO in between 2nd Ceftazidime IV (+ Avibactam 0 + 0 0 ++ ++R ++R 0 0 and 3rd gen) for Carb-Resistant Enterics) 4th Generation Cefepime IV + ++ ++ 0 ++ ++ ++R 0 0 Novel Ceftolozane-tazo/Cefiderocol 0 + + 0 ++ ++ ++ +/- 0 Carbapenems Imipenem, Meropenem IV + + + +/- ++ ++ ++R ++ 0 (+rele/vaborbactam for CRE) Ertapenem IV + ++ ++ 0 ++ ++ 0 ++ 0 Monobactam Aztreonam IV 0 0 0 0 ++ ++R + 0 0 Non β-Lactams Includes MRSA Both sp. Aminoglycosides Gentamicin,
[Show full text]
Evaluation of Efficacy of Standard Treatment of Non-Purulent Cellulitis
The Egyptian Journal of Hospital Medicine (October 2019) Vol. 77 (5), Page 5655-5661 Evaluation of Efficacy of Standard Treatment of Non-Purulent Cellulitis Abdalla Abd Al-Hamid Sallam1, Mohammed Rashed Abd Al-Hamid2, Mohammed Abd Al-Aale Yusuf Ali Nafie1, Abdalla Mohammed Al-Hady Abd Al-Aziz1 1Department of General Surgery, 2Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt *Corresponding author: Abdalla Mohammed Al-Hady Abd Al-Aziz, Mobile: (+20) 1020279742, E-Mail: [email protected] ABSTRACT Backgound: Cellulitis is commonly used to indicate a nonnecrotizing inflammation of the skin and subcutaneous tissues, a process usually related to acute infection that does not involve the fascia or muscles. Cellulitis is characterized by localized pain, swelling, tenderness, erythema, and warmth, cellulitis has been classically considered to be an infection without formation of abscess (nonpurulent), purulent drainage, or ulceration. Objective: The aim of the current work was to evaluate the efficacy of standard treatment for cases of cellulitis and identify other treatment options if needed in local community. Patients and methods: This prospective study was conducted at Department of General Surgery, Al-Azhar university hospitals (Al-Hussin & Said Galal hospitals). This study carried out on 100 consecutive patients with non-purulent cellulitis from 23/2/2017 to 1/5/2018 to allow a minimum follow-up period of at least 4 months for the last case follow upon. Clinical response to dicloxacillin, amoxicillin, and cephalexin was evaluated. Results: Age, sex, presentation, sit of non purulent cellulitis and result were recorded. Cellulitis was found to be more common in geriatric patients and slightly more in females.
[Show full text]
Antibiotics & Common Infections
Antibiotics & Common Infections Stewardship, Effectiveness, Safety & Clinical Pearls October 2016 ANTIMICROBIAL RELATED LINKS ANTIMICROBIAL STEWARDSHIP GETTING STRATEGIES TO WORK - REAL WORLD CANADIAN GUIDELINES There are world-wide efforts that look • Public, patient & provider education for strategies to deal with the challenge of over time to change expectations Bugs & Drugs (Alberta/BC): growing antimicrobial resistance. How can • Realistic appreciation for viral versus http://www.bugsanddrugs.ca/ we all work together to be stewards of this bacterial etiologies important, but limited resource? • Delayed prescriptions for select MUMS Guidelines – “Orange Book” conditions with instructions to fill only (Anti-infective Review Panel): SELECT ANTIBIOTIC RESISTANT if symptoms do not resolve or condition http://www.mumshealth.com PATHOGENS OF MAJOR CONCERN worsens. (Offer to those who value convenience.) PATIENT RESOURCES • methicillin-resistant Staphylococcus aureus (MRSA) • “It’s easy to prescribe antibiotics. It i Canadian Antibiotic Awareness: • multi-drug resistant Streptococcus takes time, energy & trust not to do so.” http://www.antibioticawareness.ca pneumonia (MRSP) Success lies in changing the culture & the which includes: • vancomycin-resistant enterococci (VRE) understanding of antibiotic limitations, • multi-drug resistant Escherichia coli & benefits & harms. 1. Viral Prescription Pad for respiratory other gram negative bacteria (e.g. ESBL) infections (download or order for free); ANTIBIOTIC HARMS – UNDERAPPRECIATED provides information about symptomatic KEY STRATEGIES FOR REDUCING ANTIBIOTICS Q To the Patient relief for viral infections and indicates when • vaccinations to prevent infections and • 1 in 5 emergency room visits for adverse patients should consider a return visit. decrease antibiotic use drug events (ADEs) are from antibiotics. • practice and educate on infection • Antibiotics are the most common cause of 2.
[Show full text]
Guidelines on Urological Infections
Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
[Show full text]
N200327s0160
Clinical Review Sheral S. Patel, M.D. NDA 200327 SD478 S-16 and S-17 Ceftaroline fosamil (Teflaro®) CLINICAL REVIEW Application Type Pediatric Efficacy Supplements Application Number(s) NDA 200327 SD478 S-16 and S-17 Priority or Standard Priority Submit Date 7 December 2015 Received Date 7 December 2015 PDUFA Goal Date 7 June 2016 Division/Office Division of Anti-Infective Products/ OAP/ OND/ CDER Reviewer Name Sheral S. Patel, M.D. Team Leader Hala Shamsuddin, M.D. Review Completion Date 13 May 2016 Established Name Ceftaroline fosamil (Proposed) Trade Name Teflaro® Applicant Cerexa, Inc. (A Subsidiary of Forest Laboratories, LLC.) Formulation(s) Powder for Injection Dosing Regimen 1. Children aged 2 months to < 2 years: 8 mg/kg every 8 hours IV administered over 5 to 60 minutes 2. Children and adolescents aged 2 years to ≤ 18 years: 12 mg/kg (up to a maximum of 400 mg for pediatric patients weighing > 33 kg) q8h by IV infusion administered over 5 to 60 minutes Applicant Proposed For the pediatric population 2 months to < 18 years Indication(s)/Population(s) 1. Acute bacterial skin and skin structure infections 2. Community acquired bacterial pneumonia Recommendation on Approval Regulatory Action Recommended For the pediatric population 2 months to < 18 years Indication(s)/Population(s) 1. Acute bacterial skin and skin structure infections (if applicable) 2. Community acquired bacterial pneumonia CDER Clinical Review Template 2015 Edition 1 Reference ID: 3933750 Clinical Review Sheral S. Patel, M.D. NDA 200327 SD478 S-16 and S-17 Ceftaroline fosamil (Teflaro®) Table of Contents Glossary ........................................................................................................................................
[Show full text]
Renal Dosage Adjustment Guidelines for Antimicrobials the Pharmacists Will Automatically Adjust the Doses of Any of the Antimicr
Renal Dosage Adjustment Guidelines for Antimicrobials The pharmacists will automatically adjust the doses of any of the antimicrobials included in the protocol according to the estimated creatinine clearance (generally using the Cockroft-Gault equation for patients ≥ 18 years old and the Schwartz equation for patients < 18 years old). This protocol does NOT include patients in the neonatal intensive care unit. For other pediatric patients less than 1 year of age the pharmacist must discuss the dose adjustment with the medical team who initiated the order. When a change is necessary, the pharmacist will write a new order in the Orders section of the medical record indicating the new dosage “per protocol” and enter the order in Carecast as a protocol (“P”) order. No physician signature will be required to authorize the revised dosing order. The adjustments listed in the dosing guidelines will be made unless the physician writes “Do not adjust” when ordering the antimicrobial. For vancomycin and the aminoglycosides, a pharmacokinetic consult will be performed by the pharmacist, and the ordering physician will be contacted for dosage changes unless ordered as “pharmacy to dose.” If written as “pharmacy to dose” dosing will be ordered by the pharmacist. The most current version of the Renal Dosage Adjustment Guidelines for Antimicrobials and associated antimicrobial policies can be found online at the antimicrobial stewardship program (ASP) website: www.nebraskamed.com/asp Please note: • If there are no clear recommendations available, the pharmacist will not perform any automatic dosage adjustment. Consult with the physician. • Accurate estimation of creatinine clearance and glomerular filtration rate from the Cockroft-Gault and Schwartz equations require serum creatinine concentrations to be at steady-state.
[Show full text]